Epigenetic CD8+ T Cell Identification via Bisulfite Convertibility
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for quantifying CD8+ cells and their subpopulations in clinical and research settings are limited by the need for fresh samples, lack of specificity in identifying CD3+CD8+ and CD3+/−CD8+ cells, and inability to differentiate between CD8 alpha/beta and alpha/alpha cells, especially in non-peripheral blood samples and solid tissues.
Innovation Solution
A method involving bisulfite convertibility analysis of specific CpG positions in the CD8 alpha and beta gene regions, allowing for the identification and quantification of CD3+CD8+ and CD3+/−CD8+ cells without cell purification, using epigenetic markers to distinguish between CD8+ subpopulations in complex samples.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If flow cytometry is used to identify and quantify CD8+ cells, then measurement precision is improved, but the method requires fresh samples and cell purification which reduces ease of operation and increases device complexity
Solution Approach 1:
The patent replaces the mechanical/physical flow cytometry system with a chemical/biochemical method based on bisulfite conversion and PCR amplification. This substitution eliminates the need for fresh samples and complex cell purification while maintaining identification accuracy through epigenetic marker detection.
Solution Approach 2:
The invention extracts and analyzes specific epigenetic markers (methylation patterns at CD8 alpha and beta gene loci) from DNA, separating the identification function from the need for intact cells. This allows analysis of archived samples without requiring fresh tissue or cell purification.
2Measurement precision
If traditional methods are used to differentiate CD8 alpha/beta and alpha/alpha cells, then measurement precision is improved, but the inability to distinguish subpopulations in solid tissues reduces adaptability
Solution Approach 1:
The patent creates a universal method that works across multiple sample types including peripheral blood, solid tissues, and archived specimens. The epigenetic marker-based approach functions consistently regardless of sample source, enabling subpopulation differentiation in previously inaccessible materials.
Solution Approach 2:
The invention changes the detection parameter from surface protein expression (flow cytometry) to DNA methylation status (epigenetic markers). This parameter change enables analysis of fixed and archived samples while maintaining the ability to distinguish CD8 subpopulations through locus-specific methylation patterns.
3Measurement precision
If cell purification and enrichment steps are performed, then measurement precision is improved, but the additional processing time and complexity reduce productivity
Solution Approach 1:
The method extracts DNA containing epigenetic markers directly from samples without requiring cell isolation or purification. This extraction approach eliminates time-consuming cell separation steps while maintaining identification accuracy through locus-specific methylation analysis.
Solution Approach 2:
The invention uses PCR amplification to create copies of specific DNA regions containing epigenetic markers, replacing the need for physical cell copies or purified cell populations. This copying approach enables accurate measurement without laborious cell purification and enrichment procedures.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables robust, reliable, and quantitative detection of CD8+ cells and subpopulations in various tissues and body fluids, providing a more stable and flexible approach for sample analysis, independent of quick sample processing and suitable for long-term storage.
Implementation Method 1
analyzing the bisulfite convertibility of at least one CpG position in the CD8 beta and CD8 alpha cell specific bisulfite convertibility gene region
Data Source
AI summary
The present invention relates to a method, in particular an in vitro method, for identifying CD8 positive subpopulations of a mammal, wherein said method comprises analyzing the bisulfite convertibility of at least one CpG position in the CD8 beta and CD8 alpha cell specific bisulfite convertibility gene region according to SEQ ID No. 1 and 2, wherein a bisulfite convertibility of at least one CpG position in said gene regions is indicative for a CD3+CD8+ and/or CD3+/−CD8+ cell. The analyses according to the invention can identify CD3+CD8+ and/or CD3+/−CD8+ cells on an epigenetic level and distinguish them from all other cells in complex samples, such as, for example, other blood cells.